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creased Aβ loads in the brain parenchyma adjacent to af-
fected vessels.  Conclusion: Our results are in line with the 
hypothesis of ABRA being the result of an excessive immune 
response to Aβ and show that this can lead to enhanced 
clearance of Aβ from the brain parenchyma by immune-me-
diated mechanisms.  © 2013 S. Karger AG, Basel 
 Introduction 
 Primary angiitis of the central nervous system 
(PACNS) is defined by focal, inflammatory vascular le-
sions confined to the brain and spinal cord without sys-
temic involvement. PACNS is rare, with an estimated in-
cidence of 2–3 cases per million per year, a median age of 
47 years, a progressive clinical course with frequent re-
currences and high lethality if not adequately treated  [1] . 
 Cerebral amyloid angiopathy (CAA) is a common 
pathological finding in the elderly, characterized by de-
position of amyloid-β (Aβ) within the cortical and men-
ingeal arteries  [2] . Its prevalence increases from 2–3% at 
the age of 70 to 15–30% at the age of 90  [2] . In Alzheimer’s 
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 Abstract 
 Background: Primary angiitis of the central nervous system 
(PACNS) is a rare but serious condition. A fraction of patients 
suffering from PACNS concurrently exhibit pronounced ce-
rebral amyloid angiopathy (CAA) which is characterized by 
deposits of amyloid-β (Aβ) in and around the walls of small 
and medium-sized arteries of the brain. PACNS with CAA has 
been identified as a distinct disease entity, termed Aβ-
related angiitis (ABRA). Evidence points to an immune reac-
tion to vessel wall Aβ as the trigger of vasculitis.  Objective: 
 To investigate whether the inflammatory response to Aβ has 
(1) any effect on the status of immune activation in the brain 
parenchyma and (2) leads to clearance of Aβ from brain pa-
renchyma.  Methods:  We studied immune activation and Aβ 
load by quantitative immunohistochemical analysis in brain 
parenchyma adjacent to affected vessels in 11 ABRA patients 
and 10 matched CAA controls.  Results: ABRA patients 
showed significantly increased immune activation and de-
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disease (AD), the prevalence of CAA is very high, possibly 
reaching 90%  [2, 3] . Almost a third of intracranial lobar 
hemorrhages in the elderly are attributed to CAA-in-
duced damage to vessel walls  [2] .
 In certain instances, patients present with coincident 
Aβ deposition in vessel walls and angiitis  [4, 5] . A variety 
of names such as granulomatous angiitis with CAA, in-
flammatory CAA or Aβ-related angiitis (ABRA) have 
been used to describe this clinicopathological entity  [4–
6] . Clinical and neuropathological investigations on 
ABRA have provided valuable insights into the pathogen-
esis of this disease  [7–9] . Regarding its pathogenesis, 
there are at least three distinct possibilities: (1) Aβ deposi-
tion in vessel walls and angiitis concur by chance as sto-
chastic events, (2) angiitis favors vessel wall deposition of 
Aβ  [10] or (3) Aβ deposition in vessel walls leads to angi-
itis  [5] . 
 In a large successive case series of biopsy-proven 
PACNS, the co-occurrence of vascular Aβ and angiitis 
was recently studied  [11–12] . Histological evidence of 
ABRA was detected in approximately 30% of PACNS 
with an average age of 46 years. Since the prevalence of 
CAA in this age group is 2–3%  [2] , chance association is 
highly unlikely. Thus, it seems that vascular Aβ deposits 
and angiitis are pathophysiologically interconnected. 
None of the studies on ABRA has provided convincing 
evidence that angiitis favors deposition of Aβ in cerebral 
vessels. Indeed, neuropathological studies showing that 
neuroinflammation is secondary to deposition of Aβ ar-
gue against the notion that inflammation promotes Aβ 
deposition  [13, 14] . Thus, the cumulative amount of evi-
dence implies that angiitis in ABRA is secondary to depo-
sition of Aβ in vessels. Already, the initial report on ABRA 
has already pointed out that angiitis may be due to vascu-
lar Aβ  [15] . Subsequent studies have shown that inflam-
mation is specific to vessels with significant Aβ deposi-
tion  [8, 16] . Furthermore, autoantibodies to Aβ can be 
observed in cerebrospinal fluid and are produced by ex-
panded B cells derived from an ABRA patient  [17, 18] . 
Finally, ABRA seems to occur spontaneously in a murine 
model with excessive production of vascular Aβ  [19] . In-
terestingly, recent therapeutic trials in AD, with active 
immunization against Aβ as the mechanistic principle, 
have drawn attention to ABRA. In patients immunized 
against Aβ, occurrence of specific antibodies seems to go 
along with clearance of Aβ from brain parenchyma, im-
mune activation and vascular inflammation  [20–22] , as 
well as potentially more prominent vessel wall deposition 
of Aβ  [23] . Therefore, in order to explore whether en-
hanced clearance of parenchymal Aβ occurs in ABRA 
and to assess whether enhanced clearance of Aβ corre-
lates with parenchymal immune activation, we carried 
out a case control study. For this, 11 patients with histo-
logically proven ABRA and 10 patients with CAA were 
chosen. To exclude bias towards enhanced Aβ loads 
found in CAA with AD  [2, 24] , we recruited ABRA and 
CAA patients according to identical criteria with no ref-
erence to cognitive status. We could show that ABRA pa-
tients harbor significantly fewer plaques in cerebral pa-
renchyma and show decreased Aβ loads compared to 
CAA controls. This reduction of plaques corresponds 
with a significant increase in activated macrophages and 
higher contents of microglia. This is in line with the hy-
pothesis that ABRA results from Aβ-triggered immune 
activation. 
 Methods 
 Patients and Controls 
 Brain tissue specimen of 11 patients with ABRA (9 from diag-
nostic biopsies and 2 from autopsies) and 10 patients with CAA 
(only diagnostic biopsies) were collected in Northern Germany 
from 2002 to 2011. For biopsy samples, vascular events leading to 
diagnostic intervention were used as entry criteria to this study. 
The 2 autopsy patients died acutely due to ABRA-related events. 
Patients with clinical signs indicative of dementia or suspected AD 
were specifically excluded from this study. Selecting patients with 
vascular events in the absence of dementia may have introduced a 
bias towards severe forms of CAA, yet bias towards elevated levels 
of parenchymal Aβ, which strongly correlates with dementia, was 
avoided. The use of specimens and basic clinical information was 
in agreement with the regulations and ethical standards of the con-
tributing hospitals and written consent by patients or relatives was 
obtained when appropriate.
 Neuropathological Investigations and Immunohistochemistry 
 Paraffin-embedded tissue samples were cut into 3-μm thick-
serial sections, mounted on glass slides and processed according to 
published protocols  [25] . Besides hematoxylin-eosin, immunohis-
tochemical stainings with the following primary antibodies were 
performed: Aβ (1: 100; Mob410; DBS Emergo  [26] ), tau (1: 1,500; 
Thermo), human leukocyte antigen-DR (HLA-DR; 1: 100; M0775, 
Dako), CD68 (1: 50; 2164; Immunotech). Primary antibodies were 
visualized using a standard diaminobenzidine streptavidin-biotin 
horseradish peroxidase method (for Aβ, tau and HLA-DR; Ven-
tana/Roche) or an alkaline phosphatase method (for CD68; Ven-
tana/Roche). Quantification of immunosignals was performed ac-
cording to published methods  [27] by experienced morphologists 
(S.B. and M.G.) blinded with respect to the experimental groups. 
Briefly, for quantification of diffuse and cored Aβ plaques, CD68-
positive macrophages, HLA-DR-positive microglia and neuro-
fibrillary tangles, we counted the presence of positive events 
(plaques, positive cells and tangles) in a representative fraction of 
the entire sample (at least 1 mm 2 ) using a Zeiss DMD 108 large 
image area microscope. For quantification of immunopositive ar-
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eas (Aβ, tau, CD68 and HLA-DR) fifteen randomly chosen 0.2-
mm 2 regions of each sample were assessed using Zeiss AxioVision 
quantification software on images taken with a Zeiss Axiovert S100 
microscope. Only parenchyma at least 200 μm distant from sites 
of angiocentric inflammation or vessels was included in the quan-
tification. 
 Statistical Analysis 
 The data were analyzed using SPSS 17 statistical software (SPSS 
Inc., Chicago, Ill., USA). Analyses included Kolmogorov-Smirnov 
and Shapiro-Wilk tests for normal distribution assessment. For 
comparison of means, Student’s t test was applied for two groups 
if they were normally distributed. Statistical significance of all 
analyses was determined at p < 0.05. 
 Results 
 Description of ABRA and CAA Cohorts  
 Details on the two patient groups are given in  table 1 . 
Within the ABRA patients (5 female, 6 male, average age 
67.5 years, standard deviation, SD, 5.2 years) the principle 
presenting complaint was acute or subacute confusion. 
Neuroimaging and biopsy (or autopsy for the 2 individu-
als who died as a consequence of ABRA; for sites of biop-
sies see  table 1 ) were performed to establish the diagnosis 
of cerebral angiitis. The CAA patients (6 female, 4 male, 
average age 68.6 years, SD 6.0 years) presented with intra-
cerebral hemorrhage without distinct signs of dementia. 
Neuroimaging and eventually biopsy (for sites of biopsies 
see  table 1 ) were performed to establish the diagnosis of 
CAA. The diagnosis of ABRA was made histologically ac-
cording to current diagnostic criteria with prominent 
transmural lymphocytic and granulomatous infiltrates, 
mainly in smaller arteries ( fig. 1 )  [5] . Deposits of Aβ could 
be seen in a substantial number of vessels. Notably, angi-
itis could only be observed in vessels with Aβ. In the CAA 
samples, well-defined Aβ deposits in the vessel walls were 
abundant. However, no signs of inflammation could be 
seen in Aβ-containing vessels ( fig. 1 ).
 ABRA Patients Have Less Aβ Plaques and Increased 
Immune Activation in Parenchyma Compared to 
CAA 
 We were interested to see whether Aβ plaques or Aβ 
loads in ABRA patients differ from those found in CAA 
Table 1.  Demographic, imagenological and clinical features of 11 ABRA and 10 control (CAA) patients
Age, 
years
Average Sex Main symptom Neuroradiological findings Site of biopsya
ABRA 70 67.5 ± 5.2 F subacute confusion multifocal leukoencephalopathy n.a.
67 M grand-mal seizure n.a. n.a.
69 M aphasia, apraxia, dementia temporal mass lesion temporal
73 F hemiparesis, progressive dementia occipital mass lesion temporal
61 M headache, confusion multiple vascular-like lesions frontal
63 M n.a. parietooccipital mass lesion parietal
78a F confusion leukoencephalopathy occipital
60 F n.a. n.a. n.a.
66 M n.a. n.a. n.a.
68 F grand-mal seizure encephalitis-like pattern n.a.
68a M progressive confusion n.a. frontal
CAA 72 68.6 ± 6.0 F n.a. intracranial hemorrhage frontal
74 F n.a. intracranial hemorrhage frontal
68 M n.a. intracranial hemorrhage frontal
63 F n.a. intracranial hemorrhage frontal
67 M n.a. subdural hygroma n.a.
76 M n.a. n.a. frontoparietal
67 F acute aphasia intracranial hemorrhage frontal
77 F n.a. n.a. parietal
56 F n.a. intracranial hemorrhage n.a.
68 M n.a. intracranial hemorrhage temporal
 n.a. = Not available. a Autopsy.
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controls. To this end, we counted Aβ plaques (diffuse and 
cored) and determined Aβ loads in brain parenchyma dis-
tant from sites of vascular inflammation. ABRA patients 
harbored significantly less Aβ plaques than CAA controls 
(16.2 ± 4.4 Aβ plaques/mm 2 for ABRA; 51.5 ± 11.4 Aβ 
plaques/mm 2 for CAA controls, p = 0.013), whereas for 
Aβ loads we detected a nonsignificant reduction in ABRA 
patients (1.2% ± 0.4/area for ABRA; 2.1% ± 1.1/area for 
CAA controls, p = 0.44;  fig. 2 ). This means that reduction 
in plaque load is more drastic than reduction in diffusely 
deposited Aβ. In contrast, tau pathology was comparable 
in both cohorts by counting tau-positive neuropil threads 
or when quantifying brain parenchyma showing tau posi-
tivity (0.31% ± 0.11/area for ABRA; 0.20% ± 0.11/area for 
CAA controls, p = 0.51; 28 ± 11 tau-positive neuropil 
threads/mm 2 for ABRA; 11 ± 14 tau-positive neuropil 
threads/mm 2 for CAA controls, p = 0.68).
 Since reduced Aβ burden has been shown to correlate 
with enhanced immune activation, and ABRA patients 
have been shown to mount an immune response to Aβ, 
we assessed immune activation in ABRA patients and 
CAA controls  [13, 14, 17, 18] . We counted CD68-positive 
macrophages and HLA-DR-positive microglia in brain 
parenchyma distant from sites of vascular inflammation 
and determined percentages of brain parenchyma show-
ing positivity for the above-mentioned markers. ABRA 
patients showed significantly more brain parenchyma 
with CD68-positive immunosignals and more CD68-
positive macrophages than CAA controls (0.98% ± 0.24/
area for ABRA; 0.24% ± 0.05/area for CAA controls, p = 
0.015; 100 ± 60 CD68-positive macrophages/mm 2 for 
ABRA; 29 ± 23 CD68-positive macrophages/mm 2 for 
CAA controls, p = 0.31;  fig. 2 ). Regarding HLA-DR-pos-
itive microglia there was no significant difference be-
tween groups (1.42% ± 0.37/area for ABRA; 1.01% ± 0.47/
area for CAA controls, p = 0.50; 84 ± 24 HLA-DR-positive 
microglial cells/mm 2 for ABRA; 58 ± 11 HLA-DR-posi-
tive microglial cells/mm 2 for CAA controls, p = 0.33). 
 Macrophages Engulf Aβ in ABRA  
 In view of the assumption that the immune response 
in ABRA might be directed against Aβ, we performed im-
munohistochemical double-labeling using antibodies di-
rected against CD68 and antibodies directed against Aβ 
in biopsies of ABRA and CAA patients. Only in ABRA 
patients could we observe CD68-positive macrophages in 
the immediate vicinity of Aβ plaques and vascular Aβ 
( fig. 3 ). We frequently found CD68-positive macrophages 
engulfing Aβ both in vessel walls ( fig. 3 a) and within the 
parenchyma at edges of Aβ plaques ( fig. 3 b).
 Discussion 
 Here we histologically analyzed the largest series of bi-
opsies from ABRA patients to date  [9] . ABRA is thought 
to be caused by an inflammatory response to Aβ depos-
ited in vessel walls  [5, 17, 18, 28] . The objective of this 
study was to investigate whether the inflammatory re-
sponse to Aβ has any effect on the status of immune acti-
vation in the brain parenchyma at sites distant from ves-
sels. Furthermore, we wanted to investigate whether this 
neuroinflammatory response would correlate with en-
hanced clearance of Aβ in ABRA. Our study clearly shows 
 Fig. 1. Representative HE and Aβ staining of ABRA (top 2 rows) 
and CAA (lower 2 rows) patient samples. Vessel walls show Aβ 
deposits in ABRA and CAA (rows 2 and 4). Inflammatory cells 
including the presence of giant cells (arrow) can only be seen in 
vessels of ABRA patients where Aβ deposits are prominent (rows 
1 and 2). Right panels show magnification of indicated regions. 
Scale bar = 100 μm. 
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that neuroinflammation in ABRA is not limited to affect-
ed vessel walls but also extends to the surrounding paren-
chyma with significantly more CD68-positive macro-
phages. This translates into a reduced Aβ plaque burden 
in these patients. We could also observe CD68-positive 
macrophages surrounding Aβ plaques and engulfing Aβ 
in ABRA but not in CAA controls, implying that the in-
flammatory response to Aβ triggered by vascular deposits 
of Aβ may lead to active clearance of parenchymal Aβ. 
 Why are these findings relevant? Over the last decade, 
ABRA has been recognized as a well-defined disease en-
tity that represents a substantial subset of PACNS  [4–6] . 
 Fig. 2. Quantification of immunohistolog-
ical staining for Aβ, tau, CD68 and HLA-
DR. Representative histological images of 
immunohistological stainings for Aβ ( a ), 
tau ( b ), CD68 ( c ) and HLA-DR ( d ) are 
shown with magnification of indicated re-
gions. Both positive events (plaques, pos-
itive cells and tangles) and percentages
of immunopositive areas were quantified 
separately and are shown as group aver-
ages for percentages of immunopositive 
areas (left part of the graph) and positive 
events (right part of the graph).  * p < 0.05, 
indicates significance (Student’s t test). 
Scale bar = 100 μm. 
*
*
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The pathophysiology of ABRA is not entirely understood, 
but the most likely etiology is excessive immune response 
to vascular Aβ  [17, 18, 28] . Our data are in line with an 
immunological origin of ABRA and suggest that the im-
munological response to Aβ extends into the brain paren-
chyma with the potentially beneficial effects of an en-
hanced clearance of Aβ. 
 There is an ongoing discussion on the presence of Aβ 
and tau deposits in ABRA. While the majority of studies 
found intermediate levels of Aβ in ABRA, the presence of 
tau is reported less frequently  [5, 29] . The fact that we 
found comparable, albeit low, amounts of tau in ABRA 
and CAA controls shows that tau deposits may be more 
frequent in ABRA than previously thought. We are confi-
dent that the observed decrease in parenchymal Aβ is not 
the result of a systemic error due to incorrect selection of 
patients. We specifically recruited patients to the CAA 
control group on the basis of vascular events leading to 
diagnostic intervention, with none of the patients present-
ing with obvious signs of AD-related dementia. The dis-
sociation between comparable tau loads and significantly 
lowered Aβ loads in ABRA patients also speaks in favor of 
selective clearance of Aβ but not tau. Similar dissociation 
could be observed in patients with active immunization 
against Aβ  [22, 30, 31] . Neuroradiological abnormalities 
have been reported in patients treated with monoclonal 
antibodies to Aβ  [32] ; these point to a correlation between 
neuroradiological findings indicative of vascular pathol-
ogy and amyloid clearance. Our data show that ABRA pa-
tients with histologically proven inflammatory vascular 
pathology have enhanced amyloid clearance, further 
highlighting similarities between ABRA and Aβ antibody-
based therapies  [33] . Taken together, our findings support 
the ever-growing evidence that autoimmune dysregula-
tion, characterized by an adaptive Aβ-directed immune 
response, plays a critical role in AD in general, but spe-
cifically in ABRA where vascular Aβ deposition may act 
as the triggering event  [13, 18, 28] . 
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 Fig. 3. Immunohistochemical double-labeling for Aβ (brown; col-
or refers to online version only) and CD68 (violet) of ABRA sam-
ples. CD68-positive activated macrophages engulfing Aβ-positive 
material can be found at the site of perivascular Aβ deposits ( a , 
unfilled arrowhead) and in the immediate vicinity of plaques in the 
cortical parenchyma ( b , solid arrowheads). 
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